Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug switching

NHS savings from adalimumab biologic switching hit earlier than expected

Adalimumab (Humira)

Source: Martin Shields / Alamy Stock Photo

Adalimumab (Humira; AbbVie) came off patent in October 2018 and was projected to achieve savings of £300m by 2021, but this is now expected one year earlier

The NHS will make financial savings from switching to biosimilar versions of adalimumab earlier than originally anticipated, according to Steve Brown, NHS England’s regional pharmacist for the south of England.

Brown told the Clinical Pharmacy Congress, which was held in London on 7–8 June 2019, that the switch programme will achieve savings of £300m by the beginning of 2020, rather than by 2021 as originally estimated.

Adalimumab (Humira; AbbVie), which is used to treat conditions such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis, came off patent in October 2018.

Brown explained that implementation of the adalimumab switch programme, which began in December 2018, has been extremely complex, with around 50,000 patients being transferred to the “best-value biologic”, predominantly via homecare providers.

The rate of uptake of best-value adalimumab has varied across different regions across England, ranging from around 20% in the West Midlands to approximately 90% in the South West, Brown said, adding that he is also looking at the barriers to uptake.

Proactive planning and communication with providers, professional networks and patient groups have been crucial to successful implementation, he told delegates.

“Where that’s happened we’ve [achieved] massive financial benefits … and the healthcare system has benefited from all of those savings very positively.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206658

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.